Abstract | OBJECTIVES: METHODS: RESULTS: There were 13 patients with moderate to severe pyoderma gangrenosum and IBD treated with infliximab. All patients demonstrated complete healing of the skin lesions. Three patients had a complete response to induction infliximab therapy and did not require additional treatment. Ten patients responded to induction infliximab and have maintained pyoderma gangrenosum healing with infusions every 4-12 wk. All patients receiving corticosteroids were able to discontinue them completely after institution of infliximab treatment. Infliximab was well tolerated; the only treatment-related adverse events were sunburn in one patient and an infusion reaction in another. CONCLUSIONS:
|
Authors | Miguel Regueiro, John Valentine, Scott Plevy, Mark R Fleisher, Gary R Lichtenstein |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 98
Issue 8
Pg. 1821-6
(Aug 2003)
ISSN: 0002-9270 [Print] United States |
PMID | 12907338
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Dermatologic Agents
- Infliximab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Dermatologic Agents
(therapeutic use)
- Female
- Humans
- Inflammatory Bowel Diseases
(complications)
- Infliximab
- Male
- Middle Aged
- Pyoderma Gangrenosum
(drug therapy, etiology)
- Retrospective Studies
|